For media enquiries about any aspect of the work of the PMCPA please contact the Press Office Direct: 02077478884 Mobile: 07920863650 firstname.lastname@example.org Sign up for eAlerts at the top of the page Follow us on Twitter @PMCPAUK FOR THE LATEST PRESS RELEASES AND TWEETS SCROLL DOWN
The PMCPA publishes certain Sanctions (advertisements, public reprimands and corrective statements) Press Releases, Case Reports and Code of Practice Reviews.
- the carrying out by the PMCPA of an audit of a company’s procedures to comply with the Code. This can also be followed by a requirement that promotional material be submitted to the PMCPA for pre-vetting for a specified period
- requiring the company to take steps to recover items from those to whom they have been given
- requiring the company to issue a corrective statement
- a public reprimand
- suspension or expulsion from membership of the ABPI.
Where companies are ruled in breach of Clause 2 of the Code, and/or are required to issue a corrective statement and/or are the subject of a public reprimand, the PMCPA advertises brief details of the cases in the medical, nursing and pharmaceutical press, the advertisements are also published on this website.
Case Reports (access Case Reports here)
As mentioned above, in some cases a company may be required to issue a corrective statement or may be the subject of a public reprimand or advertisements in the medical and pharmaceutical press.Code of Practice Review (access Code of Practice Reviews here)
The Code of Practice Review is published quarterly by the PMCPA. It includes the case reports of all cases completed within the previous three months, new advice that has been issued on the Code and an editorial relating to current matters of interest.
Otsuka Pharmaceuticals Europe Ltd and Indivior UK limited have been named in advertisements for breaches of the ABPI Code. In addition Otsuka Pharmaceuticals Europe Ltd and AstraZeneca have been publicly reprimanded.
25 June 2020read more
LAUNCH OF ABPI CONSULTATION ON PROPOSALS FOR THE ABPI CODE OF PRACTICE 2021
19 June 2020read more
COVID-19 Updates on PMCPA staffing, Seminars and Examination extensions.
18 March 2020read more
Daiichi-Sankyo, GW Pharmaceuticals, Bayer plc, Proveca Ltd, Otsuka UK and Otsuka Europe named in advertisements for breaches of the ABPI Code of Practice
27 July 2019read more
MHRA Guidance Updates - prescribing information for centrally approved products in the event of the UK leaving the EU with no deal
10 April 2019read more
Sunovion and Shield named in advertisements for breach of ABPI Code of Practice
17 December 2018read more